Toll-Like Receptor 9 (TLR-9) Modulator - Pipeline Insight, 2022

“Toll-Like Receptor 9 (TLR-9) Modulator - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Toll-Like Receptor 9 (TLR-9) Modulator pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Toll-Like Receptor 9 (TLR-9) Modulator Understanding

Toll-Like Receptor 9 (TLR-9) Modulator: Overview

The adaptive immune system has been the main focus of immunological strategies in oncology with only more recent approaches targeting innate immunity. Endosomal toll-like receptors (TLR-7, TLR-9) activate innate immune responses by signaling damage-associated molecular patterns (DAMP) from decaying tumor cells.Toll-like receptor 9 (TLR9), one of the nucleic acid-sensing TLRs, recognizes DNA fragments derived from pathogens and contributes to self-defense by activation of the innate immune system. This has led to the development of DNA-based TLR-9 agonists, which induce antitumor activity through innate and subsequent adaptive immune responses.

""Toll-Like Receptor 9 (TLR-9) Modulator - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Toll-Like Receptor 9 (TLR-9) Modulator pipeline landscape is provided which includes the disease overview and Toll-Like Receptor 9 (TLR-9) Modulator treatment guidelines. The assessment part of the report embraces, in depth Toll-Like Receptor 9 (TLR-9) Modulator commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Toll-Like Receptor 9 (TLR-9) Modulator collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Toll-Like Receptor 9 (TLR-9) Modulator R&D. The therapies under development are focused on novel approaches to treat/improve Toll-Like Receptor 9 (TLR-9) Modulator.

Toll-Like Receptor 9 (TLR-9) Modulator Emerging Drugs Chapters

This segment of the Toll-Like Receptor 9 (TLR-9) Modulator report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Toll-Like Receptor 9 (TLR-9) Modulator Emerging Drugs
• Cobitolimod: InDex Pharmaceuticals

Cobitolimod is part of InDex Pharmaceuticals’ DNA-based ImmunoModulatory Sequence (DIMS) platform. It is administered locally in the large intestine, where the substance binds to Toll-like receptor 9 (TLR9) present inside immune cells as well as on the surface of epithelial cells. The binding triggers the cells to product anti-inflammatory cytokines, agents that play an important role in reducing the inflammation and healing the wounds in the large intestine caused by UC. It is currently in Phase III for the treatment of Ulcerative colitis.
• Vidutolimod: Checkmate Pharmaceuticals

Vidutolimod activates immature pDCs through TLR9, releasing high concentrations of type I IFNα, along with a complex mixture of Th1-promoting cytokines and chemokines. This release of immune agents into the tumor and draining lymph nodes “resets” the TME making the cancer “hot.” pDC activation suppresses Treg and MDSC, attracts and activates other DCs and anti-tumor T cells into the tumor, and results in local and systemic tumor regression.

Checkmate Pharmaceuticals is investigating vidutolimod (CMP-001) across multiple tumor types in combination with checkpoint inhibitor immunotherapies in melanoma and non-melanoma skin cancers and head and neck cancer. Vidutolimod’s growing body of promising clinical data demonstrates its potential to address the unmet need for patients whose cancers are resistant to immunotherapeutic agents.

Further product details are provided in the report……..

Toll-Like Receptor 9 (TLR-9) Modulator: Therapeutic Assessment

This segment of the report provides insights about the different Toll-Like Receptor 9 (TLR-9) Modulator drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Toll-Like Receptor 9 (TLR-9) Modulator

There are approx. 15+ key companies which are developing the therapies for Toll-Like Receptor 9 (TLR-9) Modulator. The companies which have their Toll-Like Receptor 9 (TLR-9) Modulator drug candidates in the most advanced stage, i.e. Phase III include, InDex Pharmaceuticals.
• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Toll-Like Receptor 9 (TLR-9) Modulator pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Toll-Like Receptor 9 (TLR-9) Modulator: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Toll-Like Receptor 9 (TLR-9) Modulator therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Toll-Like Receptor 9 (TLR-9) Modulator drugs.

Toll-Like Receptor 9 (TLR-9) Modulator Report Insights
• Toll-Like Receptor 9 (TLR-9) Modulator Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Toll-Like Receptor 9 (TLR-9) Modulator Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Toll-Like Receptor 9 (TLR-9) Modulator drugs?
• How many Toll-Like Receptor 9 (TLR-9) Modulator drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Toll-Like Receptor 9 (TLR-9) Modulator?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Toll-Like Receptor 9 (TLR-9) Modulator therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Toll-Like Receptor 9 (TLR-9) Modulator and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• InDex Pharmaceuticals
• Scopus BioPharma
• BrightPath Biotherapeutics
• Checkmate Pharmaceuticals
• Mologen
• Exicure

Key Products
• Cobitolimod
• CO-sTiRNA
• BP-1401
• Vidutolimod
• Lefitolimod
• Cavrotolimod